Biochip Array Technology Detects Multiple Analytes

The array formats include single nucleotide polymorphism (SNP) genotyping, based on an innovative primer design that can discriminate sequences, which differ only at one base; harnessing gene expression, particularly in a multiplex array, providing a powerful insight into disease processes, such as cancer progression; rapid, sensitive, multiplex detection of viral, bacterial and protozoan pathogens; and a rapid mutation profiling array, consisting of a highly multiplexed PCR coupled to hybridization of target DNA sequences to spatially tethered probes on a biochip array.

The Sexually Transmitted Infection (STI) Array is capable of simultaneously detecting ten of the most common STIs from a single patient sample and the Respiratory Pathogens Array simultaneously detects up to 22 viral and bacterial infectious agents of the respiratory tract from bronchoalveolar lavage, nasopharyngeal swab, sputum, or saliva. The multiplex PCR and proprietary Biochip Array Technology in the analyzer known as the Evidence is a product of Randox Molecular Diagnostics (Crumlin, UK). It is well suited to the larger laboratory with a throughput of more than 1,500 tests per hour.

Personalized cancer medicine based on genetic profiling of individual tumors is regarded as the treatment strategy of the future. In respect of this, Randox Molecular Diagnostics will soon be launching a specific breast cancer-gene array for the rapid and accurate detection of mutations to stratify patients for antiepidermal growth factor receptor (EGFR)-targeted therapy. This is important, as recent clinical evidence indicates that in addition to the Kirsten rat sarcoma viral oncogene (KRAS) mutational status, other molecular alterations such as the V-raf murine sarcoma viral oncogene homolog B1 (BRAF) and Phosphoinositide 3-kinase oncogene (PIK3CA), mutations can occur in a tumor, precluding response to anti-EGFR therapy.

Related Links:
Randox Molecular Diagnostics